Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

tary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company's major efforts have been focused on projects targeting Raynaud's phenomenon, nail psoriasis and actinic keratosis. In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectation or forecasts of future events. MediQuest's performance and financial results could differ materially from those reflected in these forward-looking statements due to the decisions of regulatory authorities, ability to implement its commercial plans, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may affect the forward-looking statements please contact the Company. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. MediQuest undertakes no obligation to update publicly any forward-looking statement
www.mqti.com

Contact information
Joseph K. Piper
Managing Director, Point B Capital
jpiper@pointbcap.com
206-577-7223

Media Contact: Siavash Forootan MediQuest Therapeutics, 215-238-8881, sforootan@numodacapital.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014  Alta ... in Southern California , today announced ... technology. Alta will be providing the innovative BeClose system ... Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... providing the kind of affordable 24/7 care our clients ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
(Date:11/21/2014)... , 21. November 2014 ... heute bekannt gegeben, dass die Europäische ... die Kennzeichnung als Orphan-Medizinprodukt an Palovarotene ... Unternehmens zur Behandlung von Fibrodysplasia ossificans ... stark beeinträchtigende genetische Krankheit, die von ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Ga., Sept. 14, 2011 Greenway Medical Technologies, ... Inland Northwest Health Services (INHS) today announced an ... health record (EHR) and practice management solution ... practices requiring advanced care coordination and network interoperability. ...
... 14, 2011 Delcath Systems, Inc. (NASDAQ: ... sponsored an industry symposium at the Cardiovascular ... in Munich, Germany—the largest international forum for minimally ... radiologists in attendance. The event, held ...
Cached Medicine Technology:Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting 2Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting 3
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... 23, 2014 The report, “Market ... to 2020 - Asia-Pacific” provides quantitative analysis of ... segments: minimally invasive body contouring devices, non-invasive body ... includes market size data by revenue and volume ... countries: China, Japan, South Korea, Australia and India. ...
(Date:11/23/2014)... 23, 2014 Nearly 260 testosterone ... strokes, deep vein thrombosis and other serious cardiovascular ... multidistrict litigation (MDL) underway in the Northern District ... Court documents updated on November 17th by the ... the filing of 259 lawsuits against the makers ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released ... products are available at low rates up to 30% ... the new emergency doors. The emergency door adopts fireproof ... from several colors. All of the products are top-quality ... is not as easy as many people think. ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are ... announced its new collection of power suppliers. Additionally, it ... power suppliers. All the new models come with big ... until Dec. 20, 2014. , SWAccessControl.com has thousands of ... it for a long time. It is very wise ...
Breaking Medicine News(10 mins):Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... Make Breast Cancer ... Nov. 8 Washington State has the highest rate,of breast ... of Susan G. Komen for the Cure will host a ... policymakers to increase the budget for,screening programs for low-income women ...
... and OXFORD, England, November 8 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: ... on Tuesday, 13 November 2007. The Company is going to ... details: Date: Tuesday, 13 November 2007 Time: 02.00 p.m. ... 08.00 a.m. US time ...
... Nov. 8 World Diabetes Day, November 14,is observed ... 160 countries,and by others with an interest in diabetes. ... provides an excellent opportunity,to focus on the significant increase ... response. Funded by the National Institutes of Health ...
... Nov. 8 Repligen Corporation,(Nasdaq: RGEN ) today ... ended September 30, 2007. Total revenue for the quarter ... fiscal year,2007 ended September 30, 2006, an increase of ... of Protein A product revenue.,Gross profit on product revenue ...
... Healthcare professionals can now conduct immediate comprehensive general, health diagnosis ... ... than ever., UNION CITY, ... products company manufacturing point-of-care,blood analysis systems, announced today that the U.S. ...
... Nov. 8 Thoratec,Corporation initiated a worldwide ... Ventricular Assist Devices (IVAD) having Catalogue No.,10012-2555-001, ... and,distributed since October 2004. The current Instructions ... in the pre-peritoneal (internal) position or placed,in ...
Cached Medicine News:Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 3Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 7Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 2Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 3Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 4Health News:URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device 2
This is designed to synthesize current cardiovascular research findings for busy physicians and healthcare professionals....
Sages™ is the handheld version of The Sages Manual, a reference for the fundamentals of Laparoscopy and GI Endoscopy. It is a classic manual from the world's most pioneering society of minimally...
... This reference for third and ... clerkships enables quick study and easy ... A perfect fit for a lab ... used as a quick review prior ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: